November 25, 2019 / 9:55 PM / 17 days ago

BRIEF-ChemoCentryx And VFMCRP Announce Positive Topline Data From Pivotal Phase III ADVOCATE Trial

Nov 25 (Reuters) - ChemoCentryx Inc:

* CHEMOCENTRYX AND VFMCRP ANNOUNCE POSITIVE TOPLINE DATA FROM PIVOTAL PHASE III ADVOCATE TRIAL DEMONSTRATING AVACOPAN’S SUPERIORITY OVER STANDARD OF CARE IN ANCA-ASSOCIATED VASCULITIS

* CHEMOCENTRYX INC - TRIAL ACHIEVED BOTH PRIMARY ENDPOINTS OF CLINICAL REMISSION AT WEEKS 26 AND 52

* CHEMOCENTRYX INC - TRIAL DEMONSTRATED STATISTICAL SUPERIORITY OF AVACOPAN OVER STANDARD OF CARE (SOC) AT 52 WEEKS

* CHEMOCENTRYX INC - AVACOPAN SIGNIFICANTLY REDUCED GLUCOCORTICOID TOXICITY

* CHEMOCENTRYX INC - AVACOPAN SIGNIFICANTLY IMPROVED KIDNEY FUNCTION COMPARED TO GLUCOCORTICOID-CONTAINING SOC

* CHEMOCENTRYX INC - PLAN TO MAKE REGULATORY SUBMISSIONS OF AVACOPAN FOR FULL MARKETING APPROVAL TO BOTH EMA AND FDA IN 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below